Valrubicin
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
Journal: Journal of medical economics
Published: April 21, 2026
Cross-Species Transcriptomic and Network Analysis of Human and Canine Diffuse Large B-Cell Lymphoma Identifies a Conserved Replication-DNA Damage Module for Drug Repurposing.
Journal: Veterinary and comparative oncology
Published: February 07, 2026
Host-guest complexes of cucurbituril with the neutral guest valrubicin: an experimental and computational study.
Journal: Drug development and industrial pharmacy
Published: November 25, 2025
A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
Published: October 20, 2025
Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer.
Journal: European urology focus
Published: March 11, 2025
Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review.
Journal: Clinical genitourinary cancer
Published: December 20, 2024
NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: December 08, 2024
Multidrug micelles and sonopermeation for chemotherapy co-delivery to brain tumors.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 29, 2024
Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.
Journal: Research and reports in urology
Published: August 31, 2024
Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth.
Journal: Anticancer research
Published: August 03, 2024
Last Updated: 06/30/2026